

## The etiology of pelvic inflammatory disease with special reference to Chlamydia trachomatis

Monita Kulkarni<sup>1,\*</sup>, Ravindra Khadse<sup>2</sup>, Gopal Agrawal<sup>3</sup>

<sup>1</sup>Assistant Professor, <sup>2,3</sup>Associate Professor, Dept. of Microbiology, <sup>1</sup>Grand Government Medical College, Mumbai, Maharashtra, <sup>2</sup>Indira Gandhi Government Medical College, Nagpur, Maharashtra, Government Medical College, Nagpur, Maharashtra, India

**\*Corresponding Author: Monita Kulkarni**

Email: kulkarnimonita1975@gmail.com

### Abstract

**Introduction:** The study was carried out in a tertiary care hospital in India. 178 patients with Pelvic Inflammatory Disease (PID) were considered in the study.

**Materials and Methods:** IgG ELISA was carried out in all the patients for Chlamydia trachomatis (CT). Cervical swabs were taken and were stained by gram stain and giemsa stain. Also culture of the cervical swabs was carried out. 100 healthy controls were taken.

**Results and Discussion:** Total number of seropositive cases because of Chlamydia Trachomatis in Pelvic Inflammatory Disease cases were found to be 26.14% which was statistically significant when compared to controls which was 11%. Also the study of the etiology of Pelvic Inflammatory Disease was carried out to study the various other causative organisms of Pelvic Inflammatory Disease.

**Conclusion:** Chlamydia Trachomatis is an important causative agent of sexually transmitted infections (STI) apart from staphylococcus aureus, Escherichia Coli and Klebsiella pneumonia.

**Keywords:** Chlamydia trachomatis, Pelvic inflammatory disease, IgG ELISA, cervical swabs, Giemsa stain, Sexually transmitted infections.

### Introduction

Many different bacteria can cause PID. The acute clinical syndrome is most often attributed to ascending spread of microorganisms from cervix to the endometrium, fallopian tubes and contiguous structures. (Eschenbach et al 1975). Chlamydia trachomatis is of specific importance as it is an important organism causing PID. The main symptom of PID is persistent moderate to severe lower abdominal pain. Other symptoms include Increased or abnormal vaginal discharge, with or without odour, bleeding between periods and/or irregular periods, difficulty conceiving (infertility), painful menstruation, with symptoms that worsen with consecutive periods, frequent, painful urination, fever, pain in the upper right abdomen and painful bowel movements. Many women, however, do not have symptoms and are unaware that PID is developing. This is especially common in PID resulting from chlamydial infection. In CT infection, women develop acute urethral syndrome, bartholinitis, mucopurulent cervicitis, endometritis, salpingitis, conjunctivitis and perihepatitis. CT infection leading to PID may result in various complications like infertility, preterm labour, ectopic pregnancy due to salpingitis, perinatal morbidity and post-partum fever. (Chow et al 1974).<sup>13</sup> Chlamydia are non-motile intracellular pathogens. These intracellular pathogens are detected by light or fluorescent microscopy. Chlamydia antibodies in the serum are detected by radioimmunoassay, ELISA and complement fixation test. Antigens present in cervical swab are detected by microimmunofluorescence, counter-current immunoelectrophoresis, ELISA and radioimmunoassay. For the diagnosis of Chlamydia trachomatis its isolation and culture remains the gold standard. Culture techniques for CT are very expensive and labour intensive. In other words culture of Chlamydia trachomatis requires a complete tissue culture set up which is not available in most hospitals.<sup>6</sup>

Osborne et al (1989) opined that almost in 80% of patients with pelvic inflammatory disease, humoral antibody to Chlamydia trachomatis is present and in considerable percentage a high titre or even a rise in titre is obtained.<sup>56</sup> Thus detection of antigens or antibodies against Chlamydia trachomatis has been recommended as an alternative procedure for the diagnosis. The detection of Chlamydia trachomatis by ELISA is believed to be simple, easy and reliable technique with 100% sensitivity and about 98.5% specificity.

The various other organisms causing PID are Trichomonas vaginalis, Gardnerella vaginalis, Candida albicans, N. gonorrhoeae, Mycoplasma, Mycobacterium tuberculosis. Finding the causative agent of PID is important as its incidence has been increasing in women of the reproductive age group.<sup>14</sup>

In a study by Prabhakar et al (1989), G. vaginalis was found to be an important etiological agent in PID diagnosed in gram film by the presence of clue cells.<sup>61</sup>

Saini et al (2003) reported 73.6% aerobic isolates from endocervical swab culture consisting of E. coli 33.2%, K. pneumoniae 9.5%, Ps. aeruginosa 4.7%, Staph. aureus 14.2% and enterococci 7.1%.<sup>66</sup> Chow et al (1974) isolated 78% aerobic bacteria in cervical swab cultures which mainly constituted streptococci 22%, Staph. aureus 22%, E. coli 7%, proteus 3% and N. gonorrhoeae 13%.<sup>13</sup>

Apart from tubal obstruction and infertility, the risk of developing inclusion conjunctivitis and pneumonia to infants passing through birth canal exists. The various other organisms causing PID are Trichomonas vaginalis, Gardnerella vaginalis, Candida albicans, N. gonorrhoeae, Mycoplasma, Mycobacterium tuberculosis.

The present study was undertaken with following aims & objectives:

1. To find out the microbial profile of the PID cases in sexually active women attending Gynecology Out Patient Department.
2. To study seropositivity for CT antibody (IgM) in cases with PID.
3. To find out the seropositivity of CT antibody (IgM) in relation to risk factors for PID.

**Materials and Methods**

Patients having PID were selected who had symptoms like leucorrhoea, adnexal pain, fever, cervical motion tenderness and low back pain. Endocervical swab was taken. Also the serum sample of these patients were taken for detecting IgM antibody by ELISA.

The endocervical swabs were transported to the laboratory by amies medium. Also smears were prepared from the swabs and stained by giemsa stain and gram stain. Also culture was done on blood agar, MacConkey agar and chocolate agar.

Giemsa staining was done for inclusion bodies of CT, wet film for trophozoites of T. vaginalis & yeast cells and gram staining for clue cells suggestive of G. vaginalis and C.albicans.

**Methods**

**Microscopy:**

1. Giemsa staining for inclusion bodies of Chlamydia trachomatis.  
Smear with minimum 100 epithelial cells was taken as satisfactory. Cloak shaped intracytoplasmic basophilic inclusion bodies seen.<sup>22</sup> (Doris et al 1989)
2. Gram staining for Clue cells and microorganisms.  
Clue cells are squamous epithelial cells coated with large no. of gardnerella bacilli.<sup>16</sup> (Collee et al, 1989)
3. Wet film for trophozoites of Trichomonas vaginalis.

**Giemsa Stain:**<sup>23</sup>

Smear was fixed in methyl alcohol for 3 min.

1. Mixture of 1 part of giemsa stain and 10 parts of buffer solution (pH 7.0) was kept on the smear for 1 hour.
2. The smear was washed with buffer solution allowing preparation to differentiate for 30 min.

3. Smear was blotted and allowed to dry in air.

**Gram Staining:** Performed as per Standard laboratory technique.<sup>16</sup>

I. Cervical swab collected in Amies transport medium was inoculated on Chocolate agar, Blood agar, McConkey medium and incubated at 37<sup>0</sup> C in presence of 10% CO<sub>2</sub>. Colony morphology was studied and organisms were identified by Standard bacteriology techniques.<sup>16</sup> (Collee et al, 1989)

II. Antibiotic susceptibility of bacterial isolate was done by Kirby-Bauer disk diffusion method (Scott et al 1989) and selection of antibiotics was done as per NCCLS guidelines.<sup>76</sup>

III. Screening for Chlamydia trachomatis (IgG) antibody-  
**ELISA Test:** (Nova Tec, Chlamydia trachomatis IgG ELISA, manufactured by Nova Tec Immunodiagnostica, Germany)

**Observation**

Cases of PID were subjected to endocervical swab microscopy, culture and Chlamydia antibody (IgG) detection by ELISA. Healthy age matched controls were included to detect the seropositivity for Chlamydia antibody (IgG).

**Table 1: Microscopy and PID (n=178)**

Microscopy	Number (%)
Bacteria	78 (43.82)
Candida	4 (2.25%)
Clue Cells	8 (4.49%)
Inclusion bodies of Chlamydia	7 (3.33%)
Trichomonas vaginalis	5 (2.80%)

Different bacterial morphological forms in the gram staining were seen in 78 (43.82%) cases. Clue Cells indicating Gardnerella vaginalis were seen in 8(4.49%) out of the total 178 cases, whereas cloak shaped inclusion bodies of Chlamydia trachomatis were found in 7 (3.33%) cases. Trichomonas vaginalis was found in 5(2.80%) cases. Budding yeast cells were seen in 4(2.25%) cases.

**Table 2: Cervical swab culture and PID (n=178)**

Microbial isolate	No. of isolates (%)
Microbial growth	111 (62.35%)
Staphylococcus aureus	30 (16.85%)
E. coli	20 (11.23%)
N. gonorrhoeae	10 (5.62%)
Klebsiella pneumoniae	10 (5.62%)
Pseudomonas aeruginosa	9 (5.06%)
Enterococcus spp.	7 (3.33%)
Beta hemolytic Streptococci	6 (3.37%)
Proteus spp.	4 (2.25%)
E. Coli + Klebsiella pneumoniae	3 (1.68%)
Klebsiella pneumoniae + Pseudomonas aeruginosa	1 (0.56%)
E. coli + Proteus	1 (0.56%)
Candida albicans	10 (5.62%)
Culture negative	67(37.65%)
Total	178 (100%)

Cervical swabs from 178 clinical PID cases were cultured aerobically. Organisms were isolated from 111(62.35%) cases. Staphylococcus aureus was isolated in 30(16.85%), E. coli 20(11.23%), Klebsiella pneumoniae 10(5.62%), Pseudomonas aeruginosa 9(5.06%), Enterococci

spp. 7(3.33%), beta hemolytic Streptococci 6(3.37%), Proteus spp. 4(2.25%), Gonococci 10(5.62%) and Candida albicans in 10(5.62%), Klebsiella pneumoniae+ Pseudomonas aeruginosa, E. coli +Proteus spp. were found in 1(0.56%) case each.

**Table 3: Seropositivity for C. trachomatis in PID and control cases**

Cases	Total No. of cases	No. of C. trachomatis seropositive cases
Clinical PID	178	47 (26.40%)
Control cases	100	11 (11.00%)

Amongst 178 total clinical PID cases, 47(26.40%) cases were Chlamydia trachomatis (IgG) seropositive, while seropositivity in control cases was 11%.

The difference between PID and control cases is statistically significant (p<0.05).

**Table 4: Age group and C. trachomatis seropositive PID cases (n=178)**

Age Group	Total No. of cases of PID (%)	No. of seropositive cases
15 – 20	11 (6.18%)	3 (6.38%)
21-25	46 (25.84%)	16 (34.04%)
26 – 30	65 (36.52%)	20 (42.55%)
31 – 35	27 (15.17%)	6 (12.77%)
36 – 40	29 (16.29%)	2 (4.26%)
Total	178(100%)	47 (100%)

In the present study, seropositivity for Chlamydia antibody was maximally seen between 26-30 years of age.

**Table 5: Precipitating factors in C. trachomatis seropositive and total PID cases (n=178)**

Precipitating factors	Total No. of clinical PID cases	No. of seropositive cases
Post MTP	6 (3.37%)	1 (0.56%)
Post D & C	13 (7.30%)	2 (1.12%)
Post H SG	13 (7.30%)	1 (0.56%)
IUCD	25 (14.04%)	8 (4.49%)
Total	57(32.02%)	12(6.74%)

Out of the total 178 cases studied, predisposing factors were seen in 57(32.02%) PID cases. Out of 6 post MTP cases 1 was seropositive. In post D&C, out of the 13 cases 2 were seropositive. Seropositivity was maximum (4.49%) in IUCD cases; 25 PID cases had IUCD in situ.

**Table 6: Clinical diagnosis in PID and C. trachomatis seropositive cases. (n=178)**

	No. of PID cases	No. of seropositive cases
Cervicitis	134(75.28%) <sup>0</sup>	25(18.65%) <sup>0</sup>
Endometritis	26(14.61%)*	12(46.15%)*
Salpingitis	16(8.98%)**	10(62.50%)**
Adnexal Mass	1(0.56%)	0(0.00%)
Cyst	1(0.56%)	0(0.00%)
Total	178(100%)	47(26.40%)

\* p<0.005

\*\*p<0.005

<sup>0</sup> p<0.005

The 178 PID cases were distributed in different clinical groups on the basis of clinical diagnosis. Most cases were of cervicitis 134(75.28%), out of which 25(18.65%) cases were seropositive. This is statistically significant when compared with other PID cases (p<0.05).

Endometritis was seen in 26 (14.61%) cases of which 12(46.15%) were seropositive. Salpingitis was seen in 16 (8.98%) cases. Out of 16 cases of salpingitis 10(62.5%) were seropositive. Cervicitis and endometritis also it is statistically significant (p<0.05).

## Results and Discussion

In the current study maximum number of cases of PID had cervicitis followed by endometritis. In this study 178 PID cases were subjected to endocervical swabs for microscopy, culture and evaluation of serostatus for Chlamydia trachomatis (IgG) antibodies.

In the present study higher prevalence of PID (62.63%) was found in the age group of 21-25 years. This age group is a sexually active and child bearing age group. Gjonnaess (1982) reported 54% PID cases in this age group.<sup>32</sup> Similarly higher prevalence of PID in same vulnerable age group was reported by Westrom (1980)<sup>80</sup> {Table 4}.

It was found that gynaecological & obstretical interference like medical termination of pregnancy (MTP), dilatation & curettage (D&C), histosalpingography (HSG) and intrauterine contraceptive device (IUCD) insertion can be a cause for microbial infection of lower genital tract. These microbes later on ascend to uterus and fallopian tube from cervix. Chronic active infection caused by microbes leads to PID (Eschenbach, 1984).<sup>26</sup>

In the present study, maximum PID cases were seen with IUCD i.e. 25(14.04%). Burkman et al (1981) found 22%, Saini et al (2003) 30% of PID cases with intrauterine device for contraception.<sup>7,66</sup> Westrom (1980) showed that women who use an IUCD are at least 4 times more likely to develop PID than nonusers {Table 5}.<sup>60</sup>

Eschenbach (1984) in his epidemiological study stated that significant past history like sexually transmitted disease to either partner, infertility and complaints of acute PID in past play an important role in PID.<sup>26</sup> Berkman and Women's health study (1981) reported 52% cases of PID with previous history of pelvic inflammatory disease.<sup>8</sup> In the present study 16.85% cases had similar history. Many microbial agents responsible sexually transmitted diseases (STD) are also responsible for PID. Sevgi et al (1991) found 26% cases of PID with history of STD.<sup>71</sup> Nancy et al (1991) reported 31% PID cases with such history.<sup>54</sup> In present study 2.80% PID cases had history of STD.

Infertility is a sequelae of recurrent PID (Echenbach 1984).<sup>26</sup> Our study noted 33(18.53%) PID cases with history of infertility. Aspock et al (1995) reported 11(36.66%) and Westrom (1987) reported 17.4% PID cases with similar history.<sup>3,81</sup> Nancy et al (1991) reported 31% PID cases with history of infertility.<sup>54</sup> Hossain et al (1988) reported 20.9% seropositivity for chlamydia trachomatis in infertile patients.<sup>36</sup> Chlamydia trachomatis plays an important role in causing pelvic inflammatory diseases. These infections lead to tubal obstruction causing infertility Cetin et al(1992).<sup>10</sup> {Table3}

In the present study, 178 PID cases were distributed on the basis of their clinical groups as cervicitis (75.28%), endometritis (14.61%) and salpingitis (8.98%). (Table 6) Lal et al (1999) noted 17.3% PID cases and Lender et al (1991) reported 97% PID cases having cervicitis.<sup>42,43</sup> Cleary et al (1985) indicated 20% PID cases with salpingitis while Paavonen et al (1978) reported 70% cases.<sup>15,58</sup>

Salpingitis is often synonymous with PID; the former term should preferably be used in visually confirmed cases

only. The demonstration of the endometritis might be alternative method to identify upper genital tract infection among women who are suspected as salpingitis. Endometritis is an entity associated with PID and most likely represents an intermediate stage between cervicitis and salpingitis.<sup>57</sup> (Paavonen, 1985).Cleary et al (1985) indicated 67% PID cases with endometritis.<sup>15</sup>

In the present study, microscopic examinations of endocervical swabs were performed. Giemsa staining was done for inclusion bodies of *C. trachomatis*, wet film for trophozoites of *T. vaginalis* & yeast cells and gram staining for clue cells suggestive of *G. vaginalis*.

Inclusion bodies of Chlamydia were found in 7(3.33%) cases, clue cells in 8(4.49%) while trophozoites of *T. vaginalis* in 5(2.80%) cases of PID. {Table 1} Sheela et al (1991) reported 11.60% cases of chlamydia trachomatis inclusion bodies.<sup>73</sup> Clue cells were demonstrated in 51% and 8.5% PID cases by Ison et al (1982) and Gardner et al (1955) respectively.<sup>30,38</sup> *T. vaginalis* was seen in 3.1% cases of PID by Barbara et al (1986).<sup>4</sup>

Microbial growth was found in 62.35% of endocervical swabs cultures. *Staph. aureus* 16(16.85%) was the major isolate followed by *E. coli* 11.23%, gonococci 5.62%, *K. pneumoniae* 5.62%, *Ps. aeruginosa* 5.06%, enterococci spp 3.33%, proteus spp 2.25%, candida 5.62% and polymicrobial growth was seen in 5(2.81%) cases. {Table 2}

Saini et al (2003) reported 73.6% aerobic isolates from endocervical swab culture consisting of *E. coli* 33.2%, *K. pneumoniae* 9.5%, *Ps. aeruginosa* 4.7%, *Staph. aureus* 14.2% and enterococci 7.1%.<sup>66</sup> Chow et al (1974) isolated 78% aerobic bacteria in cervical swab cultures which mainly constituted streptococci 22%, *Staph. aureus* 22%, *E. coli* 7%, proteus 3% and *N. gonorrhoeae* 13%.<sup>13</sup> Choudhary et al (1996) isolated 100 bacterial isolates comprising of Staphylococci 28%, *E. coli* 23% and Streptococci 14%.<sup>12</sup>

Saini et al (2003) reported polymicrobial flora in 43.2% cases, while Chow et al (1975) reported 23.3% patients of PID with polymicrobial flora.<sup>14,66</sup> In the present study polymicrobial flora was observed only in 2.80% cases. Eschenbach (1984) explained that the majority of infections are caused by bacteria.<sup>26</sup> *N. gonorrhoeae*, Chlamydia trachomatis and a wide variety of aerobic and anaerobic bacteria are most frequently isolated from cervical swabs of women with PID. These organisms ascend to the uterus and fallopian tube from cervix.

Chlamydia trachomatis is one of the major pathogens responsible for PID. For the diagnosis of *C. trachomatis*, its isolation & culture remains the "Gold standard". Culture techniques for CT are very expensive & labour intensive i.e. it requires complete tissue culture set up which is not available in most of the hospitals. So in the present study an attempt is made to detect the prevalence of CT in PID cases serologically.

Amongst 178 PID cases, 26.40% were *C. trachomatis* IgG seropositive while seropositivity in control group was 11%. The difference between seropositivity of clinical PID cases & control group is statistically significant( $p < 0.05$ ). {Table 3}

Trehanne et al (1979) reported 62% seroprevalence of IgG C. trachomatis antibody in PID cases.<sup>79</sup> Similarly Mardh et al (1981) reported 37%, Gump et al (1983) 38.5%, Sheela et al (1991) 11.6% seropositivity in PID cases.<sup>34,73,45</sup>

Gynaecological & Obstetrics procedures and IUCD are responsible for fourfold rise in prevalence of PID cases (Saini et al, 2003).<sup>66</sup> In the present study, the seropositivity for C. trachomatis in PID cases with IUCD was seen in 8 (4.49%) cases {Table 12}. Westrom (1980) attributed increased incidence of PID to IUCD & legal abortions. Women who used IUCD for contraception are at least 2 to 4 times at more risk to develop PID. Guderian et al (1986) reported 47 seropositive cases with IUCD out of 176 cases of PID.

Infertility is a common problem in community. Acute PID if untreated leads to serious complications like tubal blockage and multiple adhesive lesions which cause infertility. (Eschenbach 1984)<sup>26</sup>

In the present study, 33 cases of infertility with PID were reported. {Table 13} Out of these 33 cases 6 (18.18%) were seropositive to CT. Cetin et al (1992) reported 11.6% seropositivity while Hossain et al (1988) reported 20.9% seropositivity in infertility cases.<sup>10,36</sup>

C. trachomatis plays an important role in sexually transmitted diseases. In this study, 2 out of 5(40%) PID patients having history of STD to either partner were seropositive to C. trachomatis IgG antibody. Eckert et al (1997) reported 22.5% chlamydial seropositivity in STD cases.<sup>25</sup>

Eschenbach (1984) in his study reported increase in chlamydial infection in the patients of PID with a history of similar complaints of acute PID in past.<sup>84</sup> In the present study, 8 out of 30 (26.66%) were seropositive and had the history of PID in the past.

In present study, 62.5% cases of salpingitis were seropositive for Chlamydia trachomatis. Paavonen et al (1979) reported 26% seropositivity in cases of salpingitis.<sup>59</sup> Trehanne et al (1979) found seropositivity for CT IgG antibody in 62% of acute salpingitis cases.<sup>79</sup> In the present study, 18.65% seropositive cases had cervicitis and 46.15% seropositive cases had endometritis. {Table 6}

Thus, it is observed in the present study that PID is caused by various microbial pathogens. CT is a predominant cause of PID. Intrauterine device is a common method of contraception being used by many women worldwide. The association of C. trachomatis infection in intrauterine device users is found to be higher compared to other precipitating factors leading to pelvic inflammatory disease. Thus, routine monitoring of IUCD user for C. trachomatis should be mandatory.

CT infection leading to PID, especially salpingitis can be a major cause of infertility. This was also evident in the present study. Hence early detection of C. trachomatis infection in the reproductive age group and its treatment can prevent pelvic inflammatory disease & its complications including infertility.

In the present study higher prevalence of PID (62.63%) was found in the age group of 21-25 years. This age group is a sexually active and child bearing age group. Gjonnaess

(1982) reported 54% PID cases in this age group.<sup>32</sup> Similarly higher prevalence of PID in same vulnerable age group was reported by Westrom (1980).<sup>80</sup>

In the present study, maximum PID seropositive cases were seen with Intra Uterine Contraceptive Device users.

Significant past history like sexually transmitted disease to either partner, infertility and complaints of acute PID in past play an important role in PID. In the present study, 178 PID cases were distributed on the basis of their clinical groups as cervicitis (75.28%), endometritis (14.61%) and salpingitis (8.98%).

In the present study polymicrobial flora was observed only in 2.80% cases. Apart from CT Staphylococcus aureus and Escherichia coli were found to be the common causative organisms of PID.

### Conclusion

For the diagnosis of CT, its isolation & culture remains the "Gold standard". Culture techniques for CT are very expensive & labour intensive and it requires complete tissue culture set up which is not available in most of the hospitals. So, in the present study an attempt is made to detect the prevalence of CT in PID cases serologically.

Thus, it is observed in the present study that PID is caused by various microbial pathogens. C. trachomatis is a predominant cause of PID. Intrauterine device is a common method of contraception being used by many women worldwide. The association of C. trachomatis infection in intrauterine device users is found to be higher compared to other precipitating factors leading to PID. Thus, routine monitoring of IUCD user for CT should be mandatory.

**Conflict of Interest:** None.

### References

1. Alani MD, Darogar S. "Isolation of Chlamydia trachomatis from the male urethra". *Br J Venereal Dis* 1977;53:88-92.
2. Aral OS, Mosher WD. Self-reported pelvic inflammatory disease in the United States. *JAMA* 1988;266:2570-2573.
3. Aspöck C, Bettelheim D, Fishal F, Hirsch AM, Makrisanthis A. "Infection with Chlamydia trachomatis in patients of an ambulatory sterile clinic. *Am J Obstet Gynaecol* 1995;107(14):423-426.
4. Barbara M, Shafer MA, Millstei SG. Chlamydia trachomatis and Pelvic inflammatory disease in adolescence. *J Univ California* 1986;94:143-145.
5. Bard JA, Levitt D. Binding, ingestion and multiplication of Chlamydia trachomatis in human leucocyte cell lines. *Infect Immun* 1985;50:935-937.
6. Blake J. Study on gonococcal infection IgA cleaving in vaginal washing from women with gonorrhoea. *J Infect Dis* 1997;139:1491-1494.
7. Burham RC, Martin DH. Cellular immune response during uncomplicated genital infection with Chlamydia trachomatis in human. *Infect Immun* 1981;34:98-104.
8. Burkman A and Women's Health Study. Correlation between intrauterine contraceptive device and Pelvic inflammatory disease. *J Obstet Gynaecol* 1981;3:263-270.
9. CDC: Guidelines for diagnosis of bacterial infections by Center for disease control and prevention. (Oxford press publication) 1996.

10. Cetin MT, Vardar MA. Role of Chlamydia trachomatis infection in infertility due to tubal factor. *IJMR* 1992;95:139-143.
11. Chan EL, Brandt K. A one year evaluation study of Syva Microtek Chlamydia Enzyme Immunoassay with selective confirmation by direct fluorescent antibody assay in a high volume laboratory. *J clinical Microbiol* 1994;32:2208-2211.
12. Choudhary R, Thakur R, Talwar V, Agrawal N. Anaerobic & aerobic microflora of pouch of Douglas aspirate v/s cervical swab in cases of Pelvic inflammatory disease. *IJMM* 1996;39(2):115-120.
13. Chow AW, Malkasian KL. The bacteriology of acute pelvic inflammatory disease. *Am J Obstet Gynecol* 1974;122:876-879.
14. Chow AW, Malkasian KL, Marshal JR, Lucin BG. Acute Pelvic inflammatory disease and clinical response to parental doxycycline. *Antimicrob Agents Chemother* 1975:133-138.
15. Cleary RE, Johns RB. Recovery of Chlamydia trachomatis from the endometrium in infertile women with serum antichlamydial antibodies. *Fertil Steril* 1985;44:233-235.
16. Collee JG, Marr W, Miles RS. Culture media and cultivation of bacteria. In: Mackie McCartney practical medical microbiology, 13<sup>th</sup> eds (Churchill Livingstone, London) 1989;II:102-120.
17. Conway D, Glazener CM, Caul Eo, Hodgson J, Hull MG, Stirrat GM. Chlamydial serology in fertile and infertile women. *Lancet* 1984;1(8370):191-193.
18. Daniel V, Landers MD. Pelvic inflammatory disease in united states. *Am J Obstet Gynecol* 1991;64:653-658.
19. Darougar S, Forsey T. Chlamydial genital infection in Ibadan, Nigeria. *Br J Venereal Dis* 1982;58:366-369.
20. Deak J, Nagy E. Prevalence of Chlamydia trachomatis infection in low risk population in Hungary. Prevalence of Chlamydia trachomatis infection in Pelvic inflammatory disease in South America. *Sex Trans Dis* 1997;24(9):538-542.
21. Devi PR, Menon MK, Rao KB. Chlamydia trachomatis infections. Orient Longman, Bombay 2<sup>nd</sup> ed 1986:82-89.
22. Doris M, Graham. Chlamydia. In: Mackie McCartney practical medical microbiology, 13<sup>th</sup> eds (Churchill Livingstone, London) 1989;II:38-58.
23. Duguid JP. Microscopy In: Mackie McCartney practical medical microbiology, 13<sup>th</sup> eds (Churchill Livingstone, London) 1989, vol II: 38-58
24. Dunkelburg WE, Skagg R. Method for isolation and identification of G. vaginalis. *Appl Microbiol* 1970;19:47-52.
25. Eckert LO, Haws SE, Wolner HP, Money DM, Peeling RW, Eschenbach DA et al. "Prevalence and correlates of antibody to Chlamydia heat shock protein in women attending sexually transmitted disease clinic and women with confirmed Pelvic inflammatory disease. *J Infect Dis* (1997;175(6):1453-1458.
26. Eschenbach DA. Acute Pelvic inflammatory disease. *Urol Clin North Am* 1984;11(1):65-81.
27. Eschenbach DA, Harnisch JP. Pathogenesis of acute Pelvic inflammatory disease: Role of contraception and other risk factors. *Am J Obste Gynecol* 1977;128:65-838-840.
28. Evans RT and Robinson TD. Development and evaluation of an enzyme linked immunosorbant assay (ELISA), using chlamydial group antigen, to detect antibodies to Chlamydia trachomatis. *Am J Obstet Gynecol* 1982;112:765-782.
29. Forsey T, Daroegar S. Prevalence in human beings with antibodies to chlamydia IOL-207, an atypical strain of chlamydia. *J Infect* 1986;12:145-152.
30. Gardner LH, Dukes CD. Haemophilus vaginalis vaginitis. *Am J Obstet Gynecol* 1955;69:962-976.
31. Garland Sm, Les MI, Skurrie IJ. Chlamydia trachomatis – role in tubal infertility. *Aust Nz J Obstet Gynaecol* 1990;30(1):83-86.
32. Gjonnaess H, Dalakar K. Pelvic inflammatory disease: Etiological study with emphasis on Chlamydial infections. *Am J Obstet Gynaecol* 1982;59:550-555.
33. Guderian AM, Trobough GE. Residues of Pelvic inflammatory disease in intrauterine device users a result of intrauterine device or Chlamydia trachomatis infection? *Am J Obstet Gynecol* 1986;154(3):497-503.
34. Gump DW, Gibson M. Evidence of Pelvic inflammatory disease and its relationship to Chlamydia trachomatis antibody and intrauterine contraceptive device use in infertile women. *Am J Obstet Gynecol* 1983;146:153-157.
35. Hawes LA, Gilbert GL. Serodiagnosis of Chlamydia trachomatis infection in infertile women in Melbourne. *Med J Aust* 1986;145(10):497-499.
36. Hossain A. "Serological diagnosis of Chlamydia trachomatis infections. *Int J Obstet Gynecol* 1988;27:377-380.
37. Ison H. Pelvic inflammatory disease and puerperal sepsis in Ethiopia. *Am J Obstet Gynecol* 1980;138:969-973.
38. Ison CA, Dawson SG. Comparison of culture and microscopy in the diagnosis of Gardnerella vaginalis. *J Clinical Path* 1982;35:550-554.
39. Keith L, Berger GS. The etiology of Pelvic inflammatory disease. *Res Front Fertil Regul* 1984;3(1):1-16.
40. Khurana MC, Dennish PA. Prevalence of Chlamydia trachomatis in the pregnant cervix. *Am J Obstet Gynecol* 1985;66:241-243.
41. Kihlstrom E, Lindgren R, Ryden G. Antibodies to Chlamydia trachomatis in women with infertility, Pelvic inflammatory disease and ectopic pregnancy. *Eur J Obstet Gynecol Reprod Bio* 1990;35(2-3):199-204.
42. Lal H, Rathee S, Sharma D, Chaudhary S. Detection of Chlamydia trachomatis antigen by enzyme immunoassay in patients with Pelvic inflammatory disease. *IJMR* (1992)95:77-78.
43. Lander Dv, Wolner HP, Paavonen J, Thorpe E, Eschenbach DA. Combination of antimicrobial therapy in treatment of acute Pelvic inflammatory disease. *Am J Obstet Gynecol* 1991;164(3):849-858.
44. Leonardi PA, Stavroulakis AM. Evaluation of verification assay in EIA specimens presumptively positively for Chlamydia trachomatis. *Am J Med Microbiol* 1996;44:147-150.
45. Mardh PA, Moller BR. Endometritis caused by Chlamydia trachomatis. *Br J Vener Dis* 1981;57:191-195.
46. Mardh PA Ripa T. Chlamydia trachomatis infection in patient with acute salpingitis. *N Eng J Med* 1977;296:1377-1379.
47. Meittinen A, Heinonen PK, Teisala K, Hakkarainen K, Punnonen R. Serologic evidence for the role of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma hominis in the etiology of tubal factor infertility and ectopic pregnancy. *Sex Transm Dis* 1990;17(1):10-14.
48. Melvin DG. Optimum therapy for acute Pelvic inflammatory disease. *Drugs* 1990;39(4):511-522.
49. Mithilla A, Miettinen A. Detection of serum antibodies to Chlamydia trachomatis in patients with Chlamydial and non chlamydia Pelvic inflammatory disease by the IPzyme Chlamydia and Enzyme Immunoassay. *J Clin Microbiol* 1993;31:998-1000.
50. Mittal A, Kapur S. Screening for genital chlamydial infection in symptomatic women. *IJMR* 1993;98:119-123.
51. Moore DE, Spadoni LR, Foy HM, Wang SP, Dialing JR, Eschenbach DA. Increased frequency of serum antibodies to Chlamydia trachomatis in infertility due to distal tubal disease. *Lancet* 1982;2(8298):574-577.
52. Morre SA Munk C. Comparison of three commercially available peptide based immunoglobulin IgG and IgA assay to microimmunofluorescence assay for detection of Chlamydia trachomatis antibodies. *Am J Obstet Gynecol* 2002;40:584-587.

53. Muylder DX, Laga M, Tennstedt C, Van DE, Piot P. The role of *Neisseria gonorrhoeae* and *Chlamydia trachomatis* in Pelvic inflammatory disease and its sequelae in Zimbabwe. *J Infect Dis* 1990;162(2):501-505.
54. Nancy C, Lee MD, George L. Epidemiological study of Pelvic inflammatory disease. *Am J Obstet Gynecol* 1991;77:42-50.
55. NCCLS. Performance standards for antibiotic susceptibility testing seventh ed. 2001;21(1).
56. Osborne NG, Hecht YG, Gorsline Y, Forbes J, Morgenstern F, Winkelman J. Detection of specific IgG & IgM antibodies to *Chlamydia trachomatis* in women with salpingitis confirmed by laparoscopy. *J Natl Med Asso* 1989;81:541-548.
57. Paavonen J, Anie R. Comparison of endometrial biopsy and peritoneal fluid cytologic testing with laparoscopy in the diagnosis of acute Pelvic inflammatory disease. *Am J Obstet Gynecol* 1985;151:644-650.
58. Paavonen J, Saikku P. Genital Chlamydial infections in patients attending a gynaecological outpatients clinic. *Br J Vener Dis* 1978;54:254-261.
59. Paavonen J, Saikku P, Vesterinen E, Aho K. Chlamydia trachomatis in acute salpingitis. *Br J Vener Dis* 1979;55(3):203-206.
60. Perine PL, Dunean ME, Kvasue DW, Awake S. Infertility in Pelvic inflammatory disease cases. *Am J Obstet Gynecol* 1980;138:939.
61. Prabhakar KJ. *Trichomonas vaginalis* infection Pelvic inflammatory disease. *IJPM* 1989;11:47-49.
62. Puolakkainen M, Vesterinen E, Puroala E, Saiki P, Paavonen J. Persistence of Chlamydia antibodies after Pelvic inflammatory disease. *J Clin Microbiol* 1986;924-928.
63. Ray K, Latha R, Sachdeva KG, Bohl P, Yadav S, Bhargave SC. Usefulness of immunoperoxidase test for serodiagnosis of genital chlamydial infections. *IJMR* 1993;97:67-71.
64. Richmond Sj, Sparling PF. Genital chlamydial infections. *I J Epidemiol* 1976;103:438-435.
65. Robert BJ, Ardery BR, Hill L, Cleary RE. Correlation between serum antichlamydial antibodies and tubal factors as a cause of infertility. *Infertil Steril* 1982;38:553-560.
66. Saini S, Gupta N, Aparna, Batra G, Arora DR. Role of anaerobes in acute Pelvic inflammatory disease. *IJMM* 2003;21:189-192.
67. Satpathy G, Sharma A. Species specific chlamydial antibodies in voluntary blood donors of Delhi. *IJMR* 2001;114:164-168.
68. Schachter J. Medical Progress. *N Eng J Med* 1978;298:490-495.
69. Schachter J, Causse G. Chlamydia as agents of sexually transmitted disease. Bulletin of World Health Organisation 1976;54:245-252.
70. Schwebke JR Stamm W. Use of sequential immunoassay and direct fluorescent antibody tests for the detection of *Chlamydia trachomatis* infections in women. *J Clin Microbiol* 1990;28:2473-2475.
71. Sevgi O, Aral, William D, Mosher, Willard C. Pelvic inflammatory disease in United States. *JAMA* 1991;266(18):2570-2573.
72. Sevgi O, Aral. Chlamydia trachomatis antibodies in Pelvic inflammatory disease cases. *JAMA* 1988;266:2570-2583.
73. Sheela V, Iyer, Deodhar L, Gogate A. Microbial evaluation of female patients in STD clinic. *IJMR* 1991;93:95-97.
74. Sobel JD, Mullaer G. Critical role of germ tube formation in the pathogenesis of candidal vaginitis. *Infect Immun* 1984;44:476-480.
75. Stephen RS, Kuo CC. Sensitivity of immunofluorescence with monoclonal antibodies for detection of *Chlamydia trachomatis* inclusion in cell culture. *J Clin Microbiol* 1982;16:4-7.
76. Scott AC. Laboratory control antimicrobial therapy. In: Mackie McCartney practical medical microbiology, 13<sup>th</sup> eds (Churchill Livingstone, London) 1989;II:38-58
77. Treharne JD, Darougar S. Modification of the microimmuno fluorescence test to provide a routine serodiagnostic test for chlamydial infection. *J Clin Path* 1977;30:510-517.
78. Treharne JD, Darougar S, Simmons PD, Thin RN. Rapid diagnosis of chlamydial infection of cervix. *Br J Vener Dis* 1978;54(6):403-408.
79. Treharne JD, Ripa KT. Antibodies to *Chlamydia trachomatis* in acute salpingitis. *Bri J Vener Dis* 1979;55:26-29.
80. Westrom L. Incidence, prevalence and trends of acute Pelvic inflammatory disease and its consequences in industrialized countries. *Am J Obstet Gynecol* 1980;128:621-627.
81. Westrom L. Pelvic inflammatory disease: Bacteriology and Sequelae. *Contracept* 1987;36(1):111-128.
82. Wyrick PB, Choong J. Entry of genital *Chlamydia trachomatis* in to polarized human epithelial cells. *Infect Immun* 1989;2378-2390.

**How to cite this article:** Kulkarni M, Khadse R, Agrawal G. The etiology of pelvic inflammatory disease with special reference to *Chlamydia trachomatis*. *Indian J Microbiol Res* 2019;6(1):82-88.